- Preparation method of escitalopram oxalate demethylation impurity
-
The invention provides a brand-new preparation method of 1-(4- fluorophenyl)-1-(3-(fluorophenyl)propyl)-1,3-dihydroisobenzofiaran-5-formonitrile as an escitalopram oxalate process impurity. The brand-new preparation method provides a reference for qualitatively and quantitatively analyzing impurity conditions in a finished product of escitalopram oxalate, has an important effect on quality control of the escitalopram oxalate, and can promote safe medication of depressed patients.
- -
-
Paragraph 0017
(2017/08/29)
-
- Design, synthesis, and biological evaluation of a series of bifunctional ligands of opioids/SSRIs
-
A series of opioid and serotonin re-uptake inhibitors (SSRIs) bifunctional ligands have been designed, synthesized, and tested for their activities and efficacies at μ-, δ- and κ opioid receptors and SSRIs receptors. Most of the compounds showed high affinities for μ- and δ-opioid receptors and lower affinities for SSRIs and κ opioid receptors. A docking study on the μ-opioid receptor binding pocket has been carried out for ligands 3-11. The ligands 7 and 11 have displayed the highest binding profiles for the μ-opioid receptor binding site with ΔGbind (-12.14 kcal/mol) and Ki value (1.0 nM), and ΔGbind (-12.41 kcal/mol) and Ki value (0.4 nM), respectively. Ligand 3 was shown to have the potential of dual acting serotonin/norepinephrine re-uptake inhibitor (SNRI) antidepressant activity in addition to opioid activities, and thus could be used for the design of multifunctional ligands in the area of a novel approach for the treatment of pain and depression.
- Mehr-Un-Nisa,Munawar, Munawar A.,Lee, Yeon Sun,Rankin, David,Munir, Jawaria,Lai, Josephine,Khan, Misbahul A.,Hruby, Victor J.
-
p. 1251 - 1259
(2015/03/04)
-
- Novel and high affinity fluorescent ligands for the serotonin transporter based on (S)-citalopram
-
Novel rhodamine-labeled ligands, based on (S)-citalopram, were synthesized and evaluated for uptake inhibition at the human serotonin, dopamine, and norepinephrine transporters (hSERT, hDAT, and hNET, respectively) and for binding at SERT, in transiently
- Kumar, Vivek,Rahbek-Clemmensen, Troels,Billesb?lle, Christian B.,Jorgensen, Trine Nygaard,Gether, Ulrik,Newman, Amy Hauck
-
p. 696 - 699
(2014/07/07)
-
- PERMANENTLY POSITIVELY CHARGED ANTIDEPRESSANTS
-
The present invention provides compounds comprising a substructure of below formula 3: or a salt or prodrug thereof and the use of such compounds in treatment of e.g. CNS disorders.
- -
-
Page/Page column 65
(2013/03/26)
-
- Enantioenriched synthesis of Escitalopram using lithiation-borylation methodology
-
The asymmetric synthesis of Escitalopram has been completed using a lithiation-borylation reaction as the key step. Suitably functionalized enantioenriched carbamate (er 98:2) and boronic ester coupling partners were prepared and following deprotonation with s-BuLi and borylation, the tertiary alcohol was obtained in 42% yield and 93:7 er. The lithiation-borylation reaction was found to tolerate nitrile, benzylic alcohol and N-Boc functionalities. The tertiary alcohol was converted to Escitalopram in three further steps.
- Partridge, Benjamin M.,Thomas, Stephen P.,Aggarwal, Varinder K.
-
p. 10082 - 10088
(2012/02/05)
-
- Process for the Preparation of Escitalopram
-
The present invention provides a novel process for the preparation of a compound of Formula III, and novel processes for preparing escitalopram using the compound of Formula III.
- -
-
Page/Page column 8
(2010/08/18)
-
- Process for the preparation of escitalopram
-
The present invention relates to a novel process for the preparation of Escitalopram, which comprises: (ii) de-methylating (±)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile (Formula II) (Citalopram) to produce (±)-1-[3-(methylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile (desmethyl Citalopram) (XII), (iii) isolating the pure desmethyl Citalopram (XII), (iv) separating the enantiomers from the pure desmethyl Citalopram (XII) with an optically active acid to obtain (S)-(+)-1-[3-(methylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile ((S)-(+)-desmethyl Citalopram) (XIII), (v) methylating an enantiomerically pure compound (XIII) using suitable methylating agent to produce Escitalopram (I).
- -
-
Page/Page column 10
(2009/02/10)
-
- Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites
-
Methods for prophylaxis of or treating or preventing migraine or migraine headaches, or other headache disorders include administering to a subject in need of treatment a therapeutically effective amount of citalopram, escitalopram, or a racemic or optically pure citalopram metabolite, or pharmaceutically acceptable salts, solvates, polymorphs, or hydrates thereof.
- -
-
Page/Page column 11
(2010/02/13)
-
- Gas phase production of [11C]methyl iodide-d3. Synthesis and biological evaluation of S-[N-methyl-11C]citalopram and deuterated analogues
-
Three 11C-labelled tracers for the serotonin reuptake site, S-[N-methyl-11C]citalopram ([11C]-4), S-[N-methyl-d 3-11C]citalopram ([11C]-12), and S-[N-methyl-11C]citalopram-α,α-d
- Madsen, Jacob,Elfving, Betina,Andersen, Kim,Martiny, Lars,Knudsen, Gitte M.
-
p. 335 - 348
(2007/10/03)
-
- Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes
-
The involvement of CYP enzymes in the metabolism of citalopram was studied, inclusive the conversion of demethylcitalopram to didemethylcitalopram and the formation of citalopram N-oxide, which both have not been considered previously. Using human mixed liver microsomes and cDNA-expressed CYP enzymes, we confirmed that CYP3A4, 2C19 and 2D6 are involved in the first demethylation step of citalopram, all favouring conversion of the biologically active S-enantiomer. Inhibitor studies indicated that at therapeutic citalopram concentrations CYP3A4 was responsible for 40-50% of demethylcitalopram formation, while the contribution of CYP2C19 increased and that of CYP2D6 tended to decrease with increasing drug concentration, CYP2D6 exclusively mediated the second demethylation step, and citalopram N-oxide was also exclusively formed by CYP2D6. None of the studied CYP enzymes mediated deamination to the propionic acid derivative.
- Olesen, Ole V.,Linnet, Kristian
-
p. 298 - 309
(2007/10/03)
-